Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.


CSE:RVV - Post by User

Revive Therapeutics Ltd. > Great read, reasons why the Phase 3 trial will be a success.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(6)
•••
Comment by Dmfb12on Sep 15, 2021 10:51pm
119 Views
Post# 33866983

RE:RE:RE:RE:RE:RE:Great read, reasons why the Phase 3 trial will be a success.

RE:RE:RE:RE:RE:RE:Great read, reasons why the Phase 3 trial will be a success.Yeah that post was nothing but lambs, moons emojis and pointless content, no substance and sources to back up his points....

can't win with u, it's either stupid cause it's a paid promotion or someone pumping

how about a response from you that has an ounce of substance like that Reddit link did. I might actually be impressed by your comments for once 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities